Kalaris Therapeutics Q2 net loss narrows on lower administrative costs
KLRS•Outlook and cash runway
Kalaris expects preliminary data from its Phase 1b/2 TH103 study in the first half of 2027.
The company plans to initiate potential Phase 3 trials by year-end 2027.
Kalaris said cash reserves fell to $93.5 million and are expected to fund operations into the fourth quarter of 2027 and through key clinical milestones.
Cost drivers in the quarter
Higher research and development expenses were mainly due to increased clinical activity for TH103, including opening more investigational sites and enrolling patients.
That increase was partially offset by decreased manufacturing and process development spending.
General and administrative expenses declined due to decreased legal, accounting and other professional fees.
Key figures and analyst view
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Loss Per Share | Beat | $0.48 | $0.50 (8 Analysts) |
| Q2 Net Loss | Beat | $11.52 million | $12.14 million (7 Analysts) |
| Q2 Operating Income | Slight Beat* | -$12.39 million | -$12.49 million (6 Analysts) |
| Q2 Operating Expenses | $12.39 million |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell".
Related News
Bicara Therapeutics releases corporate deck highlighting ficerafusp alfa EGFR-TGF-β program in HPV-negative head and neck cancer
Cantor Equity Partners II Inc <SECZ.N>: Citizens initiates coverage with market outperform rating; target price $15
